Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin

29 out of 30 participants were retained to the week-2 primary endpoint in a study on psilocybin-assisted psychotherapy.

• Participants with treatment-resistant depression received one to three doses of psilocybin at a fixed dose of 25 mg.
• Greater reductions in depression severity were observed in the immediate treatment group compared to the waitlist group, with a large effect size of 1.07.
• Adverse events were transient, and no serious adverse events occurred during the study.
• Repeated doses of psilocybin were associated with further reductions in depression severity compared to baseline.
• The study suggests that psilocybin-assisted psychotherapy may be feasible and safe for complex patients with high treatment resistance.

AI simplified